innerthera bpc 157 Original – Infiniwell Wolverine Stack Peptide Therapy (BPC-157

The follow-up pivotal trial (METAOD006 / OPTIONS) enrolled a larger cohort and failed to replicate statistically significant weight loss, which led Metabolic Pharmaceuticals to halt the formal drug development program in 2007

Children born to mothers with low B12 levels may have excess fat accumulation which in turn can result in higher insulin resistance and risk of T2D and/or CVD in adulthood

The content is not intended to encourage application, diagnosis, or self-treatment of unlicensed individuals, and should not be used as a substitute for the clinical judgment of a qualified healthcare provider

Recommended to be used within 90 days of opening